Lexeo (LXEO) officer now holds 65,862 shares; 49,138 RSUs included

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO) insider filing: the Chief Development Officer reported equity transactions on a Form 4. On 10/15/2025, the officer acquired 10,890 shares of Common Stock at $0, reflecting the release of RSUs. On 10/17/2025, the officer sold 3,844 shares at a weighted average price of $8.935 (executed between $8.53 and $9.52) and 44 shares at a weighted average price of $9.561 (executed between $9.53 and $9.59). The filing states the sales were to cover tax obligations upon RSU release. Following these transactions, the officer beneficially owned 65,862 shares directly, which includes 49,138 RSUs, each representing a right to receive one share.

Insider Trade Summary

Net Seller: 3,888 shares ($34,767)

Net Sell 3 txns

Insider See Tai Sandi

Role Chief Development Officer

Sold 3,888 shs ($35K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,844	$8.935	$34K
Sale	Common Stock	44	$9.561	$420.68
Grant/Award	Common Stock	10,890	$0.00	--

Holdings After Transaction: Common Stock — 65,906 shares (Direct)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 49,138 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

See Tai Sandi

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		A		10,890	A	$0	69,750	D
Common Stock	10/17/2025		S(1)		3,844	D	$8.935(2)	65,906	D
Common Stock	10/17/2025		S(1)		44	D	$9.561(3)	65,862(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. Includes 49,138 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lexeo Therapeutics (LXEO) disclose in this Form 4?

An officer reported RSU-related share acquisition and sales, including 10,890 shares acquired on 10/15/2025 and small sales on 10/17/2025.

How many shares were sold and at what prices in the LXEO Form 4?

On 10/17/2025, the officer sold 3,844 shares at a $8.935 weighted average and 44 shares at a $9.561 weighted average.

Why were shares sold by the LXEO officer?

The filing notes the sales were to cover tax obligations upon the release of RSUs.

What is the officer’s beneficial ownership after the transactions?

The officer held 65,862 shares directly after the reported trades, including 49,138 RSUs.

What role does the reporting person hold at LXEO?

The reporting person is an Officer, serving as Chief Development Officer.

What are RSUs mentioned in the LXEO Form 4?

RSUs are Restricted Stock Units, each representing a contingent right to receive one share of Common Stock upon vesting.